KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Prepaid Assets (2020 - 2025)

AbCellera Biologics' Prepaid Assets history spans 6 years, with the latest figure at $133.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Prepaid Assets rose 206.68% year-over-year to $133.0 million, compared with a TTM value of $133.0 million through Sep 2025, up 206.68%, and an annual FY2024 reading of $67.1 million, up 20.3% over the prior year.
  • Prepaid Assets for Q3 2025 was $133.0 million at AbCellera Biologics, up from $116.8 million in the prior quarter.
  • The five-year high for Prepaid Assets was $133.0 million in Q3 2025, with the low at $4.9 million in Q2 2021.
  • Average Prepaid Assets over 5 years is $56.6 million, with a median of $55.8 million recorded in 2023.
  • Year-over-year, Prepaid Assets surged 792.82% in 2022 and then plummeted 43.01% in 2024.
  • Tracing ABCL's Prepaid Assets over 5 years: stood at $21.2 million in 2021, then skyrocketed by 254.93% to $75.4 million in 2022, then decreased by 25.99% to $55.8 million in 2023, then increased by 20.3% to $67.1 million in 2024, then soared by 98.11% to $133.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Prepaid Assets are $133.0 million (Q3 2025), $116.8 million (Q2 2025), and $94.7 million (Q1 2025).